Finance Home - Yahoo! - Help

Biogen Idec Inc. Earnings Conference Call (Q4 2004)  Today's Calls

Visit the CCBN Network· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Yahoo! Player Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 7 Calls Today's Calls

Call Details Biogen Idec Inc. Earnings Conference Call (Q4 2004) Scheduled to start Mon, Feb 7, 2005, 5:00 pm Eastern Check back at the scheduled start time for the audio link to appear in this spot. Add This Event To Your Yahoo! Calendar After the event has finished, the audio will be available from this page until Tue, Mar 8, 2005 About Biogen Idec Inc. (NasdaqNM:BIIB) Other Calls  Biogen Idec Inc. develops, manufactures and commercializes novel therapies. As of December 31, 2003, it had four commercial products: Avonex (Interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS), Rituxan (rituximab) and Zevalin (ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas, also referred to as B-cell NHLs, and Amevive (alefacept) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The Company also receives revenues from royalties on sales by its licensees of a number of products covered under patents that it controls including sales of Rituxan outside the United States. The Company was formed via the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation. More from Reuters: Expanded Business Description More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings